Substance / Medication

Tocainide

Overview

Active Ingredient
tocainide
RxNorm CUI
42359

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.
De Luca Annamaria, Pierno Sabata, Liantonio Antonella et al. · Neuromuscul Disord · 2004
PMID: 15210163Observational
Effect of acidity on the enantiomeric resolution of thyroxine and tocainide by HPLC on a (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid column.
Aboul-Enein Hassan Y, Ali Imran, Hyun Myung Ho et al. · J Biochem Biophys Methods · 2002
PMID: 12543515Observational
A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues.
Carocci Alessia, Corbo Filomena, Lentini Giovanni et al. · Curr Med Chem · 2018
PMID: 29589531Review
Tocainide analogues binding to human serum albumin: a HPLAC and circular dichroism study.
Pistolozzi Marco, Franchini Carlo, Corbo Filomena et al. · J Pharm Biomed Anal · 2010
PMID: 20359840Other
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.
De Bellis Michela, Carbonara Roberta, Roussel Julien et al. · Neuropharmacology · 2017
PMID: 27743929PreclinicalFull text (PMC)
N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels.
Muraglia Marilena, De Bellis Michela, Catalano Alessia et al. · J Med Chem · 2014
PMID: 24568674Preclinical
Species-dependent binding of tocainide analogues to albumin: affinity chromatography and circular dichroism study.
Pistolozzi Marco, Fortugno Cecilia, Franchini Carlo et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2014
PMID: 24472243Preclinical
Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models.
Ghelardini C, Desaphy J-F, Muraglia M et al. · Neuroscience · 2010
PMID: 20580661Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tocainide (substance)
SNOMED CT
372479006
UMLS CUI
C0085237
RxNorm CUI
42359

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.